NO984418L - Arylaminokondenserte pyridiner og pyrimidiner - Google Patents

Arylaminokondenserte pyridiner og pyrimidiner

Info

Publication number: NO984418L
Authority: NO; Norway
Prior art keywords: arylamino; pyrimidines; condensed pyridines; pyridines; condensed
Prior art date: 1996-03-27

Application number

NO984418A

Other languages

English (en)

Norwegian (no)

Other versions

NO984418D0 (no

Inventor

Rajagopal Bakthavatchalam

Argyrios Georgios Arvanitis

James Peter Beck

Gary Avonn Cain

Robert John Chorvat

Paul Joseph Gilligan

Original Assignee

Du Pont Pharm Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-27

Filing date

1998-09-22

Publication date

1998-11-03

1998-09-22 Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co

1998-09-22 Publication of NO984418D0 publication Critical patent/NO984418D0/no

1998-11-03 Publication of NO984418L publication Critical patent/NO984418L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Luminescent Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO984418A 1996-03-27 1998-09-22 Arylaminokondenserte pyridiner og pyrimidiner NO984418L (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US1415796P	1996-03-27	1996-03-27
US64661296A	1996-05-08	1996-05-08
US3053696P	1996-10-31	1996-10-31
US3912497P	1997-02-25	1997-02-25
PCT/US1997/004852 WO1997035539A2 (fr)	1996-03-27	1997-03-25	Pyridines et pyrimidines a fusion arylamino

Publications (2)

Publication Number	Publication Date
NO984418D0 NO984418D0 (no)	1998-09-22
NO984418L true NO984418L (no)	1998-11-03

Family

ID=27486365

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO984418A NO984418L (no)	1996-03-27	1998-09-22	Arylaminokondenserte pyridiner og pyrimidiner

Country Status (21)

Country	Link
US (2)	US6107300A (fr)
EP (1)	EP0935601A4 (fr)
JP (1)	JP2002515032A (fr)
KR (1)	KR20000005037A (fr)
CN (1)	CN1230184A (fr)
AU (1)	AU2545897A (fr)
BR (1)	BR9708261A (fr)
CA (1)	CA2250241A1 (fr)
CZ (1)	CZ304098A3 (fr)
EA (1)	EA199800868A1 (fr)
EE (1)	EE9800329A (fr)
HR (1)	HRP970173A2 (fr)
HU (1)	HUP9902340A3 (fr)
IL (1)	IL126316A0 (fr)
LV (1)	LV12262B (fr)
NO (1)	NO984418L (fr)
NZ (1)	NZ331874A (fr)
PL (1)	PL335258A1 (fr)
SI (1)	SI9720026A (fr)
SK (1)	SK131798A3 (fr)
WO (1)	WO1997035539A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1066147C (zh)	1995-11-01	2001-05-23	诺瓦提斯公司	嘌呤衍生物及其制备方法
CN1251100A (zh) *	1997-03-21	2000-04-19	杜邦药品公司	芳氨基三唑并吡啶的制备方法
AU8181098A (en) *	1997-07-03	1999-01-25	Du Pont Pharmaceuticals Company	Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
US6156898A (en) *	1998-02-26	2000-12-05	Neurogen Corporation	Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands
WO2000027846A2 (fr)	1998-11-12	2000-05-18	Neurocrine Biosciences, Inc.	Antagonistes de recepteurs du crf et methodes associees
JP2002529469A (ja)	1998-11-12	2002-09-10	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
US6531475B1 (en)	1998-11-12	2003-03-11	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
GB9903762D0 (en)	1999-02-18	1999-04-14	Novartis Ag	Organic compounds
AU7738000A (en)	1999-09-30	2001-04-30	Neurogen Corporation	Certain alkylene diamine-substituted heterocycles
WO2001044257A1 (fr) *	1999-12-17	2001-06-21	Ariad Pharmaceuticals, Inc.	Inhibiteurs de la pompe a protons
US7115589B2 (en) *	1999-12-17	2006-10-03	Ariad Pharmaceuticals, Inc.	Purine derivatives
AU2001232271A1 (en) *	2000-02-14	2001-08-20	Japan Tobacco Inc.	Preventives/remedies for postoperative stress
JP2004532792A (ja)	2000-07-14	2004-10-28	ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー	神経障害を治療するためのイミダゾ［１，２−ａ］ピラジン
YU63703A (sh)	2001-02-12	2006-05-25	F. Hoffmann-La Roche Ag.	6-supstituisani pirido-pirimidini
DE60218434T2 (de)	2001-03-13	2007-11-08	Bristol-Myers Squibb Pharma Co.	4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
DE60217669D1 (de)	2001-05-14	2007-03-08	Bristol Myers Squibb Co	Substitutierte pyrazinone, pyridine und pyrimidine als corticotropin-releasing-factor liganden
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
WO2003005969A2 (fr)	2001-07-12	2003-01-23	Bristol-Myers Squibb Pharma Company	Tetrahydropurinones et leurs derives en tant que ligands du recepteur du facteur de liberation de corticotropine
WO2003006015A1 (fr)	2001-07-13	2003-01-23	Bristol-Myers Squibb Pharma Company	Thiazoles et oxazoles substitutes utilises comme ligands hormonaux de liberation de la corticotrophine
GB0117522D0 (en)	2001-07-19	2001-09-12	Procter & Gamble	Solvent welding process
GB0117525D0 (en)	2001-07-19	2001-09-12	Procter & Gamble	Solvent welding process
US20030119831A1 (en)	2001-11-20	2003-06-26	Hartz Richard A.	3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
US9967633B1 (en)	2001-12-14	2018-05-08	At&T Intellectual Property I, L.P.	System and method for utilizing television viewing patterns
AU2002359732A1 (en) *	2001-12-17	2003-06-30	Ribapharm Inc.	Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
GB0219746D0 (en)	2002-08-23	2002-10-02	Inst Of Ex Botany Ascr	Azapurine derivatives
SE0301373D0 (sv) *	2003-05-09	2003-05-09	Astrazeneca Ab	Novel compounds
WO2005009348A2 (fr) *	2003-06-25	2005-02-03	Ariad Pharmaceuticals, Inc.	Derives de purine substitues
KR20060072142A (ko) *	2003-09-09	2006-06-27	오노 야꾸힝 고교 가부시키가이샤	Ｃｒｆ 길항제 및 이환식 복소환 화합물
ES2651730T3 (es) *	2003-09-26	2018-01-29	Exelixis, Inc.	Moduladores c-Met y métodos de uso
JP2007526339A (ja) *	2004-03-02	2007-09-13	ニューロジェン・コーポレーション	アリール置換プリン類縁体
EP1598354A1 (fr) *	2004-05-18	2005-11-23	Vasopharm Biotech GmbH	Composes contenant un groupement n-heteroaryle lie a un cycle condense et leur utilisation comme inhibiteurs du nad(p)h oxidases et de l'activation plaquettaire
EP1773826A4 (fr) *	2004-07-02	2009-06-03	Exelixis Inc	Modulateurs de c-met et leur methode d'utilisation
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
WO2006010264A1 (fr) *	2004-07-30	2006-02-02	Methylgene, Inc.	Inhibiteurs de signalisation de recepteur du facteur de croissance endotheliale (vegf) et de recepteur de facteur de croissance des hepatocytes (hgf)
ATE421518T1 (de) *	2005-02-10	2009-02-15	Bristol Myers Squibb Co	Dihydrochinazolinone als 5ht-modulatoren
EP1703668A1 (fr) *	2005-03-18	2006-09-20	Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO	Système pour traiter des paramètres "qualité de service" (qos) dans un réseau de communications
EP1957498B1 (fr) *	2005-05-20	2017-02-15	MethylGene Inc.	Inhibiteurs de la signalisation du récepteur vegf et du récepteur hgf
EP1904504B1 (fr) *	2005-05-20	2014-03-19	MethylGene Inc.	Inhibiteur de la signalisation du recepteur vegf et hgf
US7973025B2 (en)	2005-05-26	2011-07-05	Neuron Systems, Inc.	Compositions and methods of treating retinal disease
EA200800430A1 (ru) *	2005-07-28	2008-06-30	Бристол-Маерс Сквибб Компани	Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
US7795436B2 (en) *	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
BRPI0618636A2 (pt) *	2005-11-08	2011-09-06	Hoffmann La Roche	derivados de tiazolo [4,5-c]piridina
PE20080145A1 (es) *	2006-03-21	2008-02-11	Janssen Pharmaceutica Nv	Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2007107005A1 (fr) *	2006-03-22	2007-09-27	Methylgene, Inc.	Inhibiteurs de l'activité protéine tyrosine kinase
EP2044086A2 (fr) *	2006-06-30	2009-04-08	Janssen Pharmaceutica N.V.	Modulateurs de trpv1 à base de thiazolopyrimidine
CA2668182A1 (fr)	2006-10-31	2008-05-08	Janssen Pharmaceutica N.V.	Derives de triazolopyrimidine convenant comme antagonistes du recepteur p2y12 de l'adp
WO2008054795A2 (fr) *	2006-10-31	2008-05-08	Janssen Pharmaceutica, N.V.	Dérivés de triazolopyrimidine convenant comme antagonistes du récepteur p2y12 de l'adp
CA2673654A1 (fr) *	2007-01-10	2008-07-17	Albany Molecular Research, Inc.	Indazoles 5-pyridinone substituees
BRPI0814772A2 (pt) *	2007-07-21	2015-03-03	Albany Molecular Res Inc	Indazóis substituídos por 5-piridinona
WO2009078999A1 (fr)	2007-12-17	2009-06-25	Janssen Pharmaceutica N.V.	Modulateurs imidazolo-, oxazolo- et thiazolopyrimidines de trpv1
EP2332536A1 (fr) *	2008-03-05	2011-06-15	MethylGene Inc.	Inhibiteurs d'activité de kinase de tyrosine de protéine
US8273900B2 (en)	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
CA2758030C (fr)	2009-01-16	2019-01-08	Exelixis, Inc.	Sel de malate de n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2782015C (fr)	2009-12-11	2020-08-25	Neuron Systems, Inc.	Compositions ophthalmiques topiques et methodes de traitement de la degenerescence maculaire
EP2919788A4 (fr)	2012-11-14	2016-05-25	Univ Johns Hopkins	Méthodes et compositions pour le traitement de la schizophrénie
HK1217439A1 (zh)	2013-01-23	2017-01-13	Aldeyra Therapeutics, Inc.	与毒性醛相关的疾病和治疗
US9868744B2 (en)	2014-04-25	2018-01-16	Pfizer Inc.	Heteroaromatic compounds and their use as dopamine D1 ligands
EP3259274B1 (fr) *	2015-02-18	2023-06-28	Buck Institute for Research on Aging	Triazolopyridines et triazolopyrimidines qui abaissent la p-tau provoquée par le stress
MX2018002155A (es)	2015-08-21	2018-06-08	Aldeyra Therapeutics Inc	Compuestos deuterados y usos de los mismos.
US11370793B2 (en)	2015-08-27	2022-06-28	Nantneuro, Llc	Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
JP7311162B2 (ja)	2017-10-10	2023-07-19	アルデイラセラピューティクス，インコーポレイテッド	炎症性障害の処置
JP2021527687A (ja) *	2018-06-21	2021-10-14	ヤンセンファーマシューティカエヌ．ベー．	Ｏｇａ阻害剤化合物
WO2020033344A1 (fr) *	2018-08-06	2020-02-13	Aldeyra Therapeutics, Inc.	Composés polymorphes et leurs utilisations
US12098132B2 (en)	2019-05-02	2024-09-24	Aldeyra Therapeutics, Inc.	Process for preparation of aldehyde scavenger and intermediates
WO2020223685A1 (fr)	2019-05-02	2020-11-05	Aldeyra Therapeutics, Inc.	Composés polymorphes et leurs utilisations
WO2021231792A1 (fr)	2020-05-13	2021-11-18	Aldeyra Therapeutics, Inc.	Formulations pharmaceutiques et leurs utilisations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1544419A (en) *	1975-11-19	1979-04-19	Science Union & Cie	Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4076711A (en) *	1976-04-05	1978-02-28	Schering Corporation	Triazolo [4,5-d]-pyrimidines
EP0155911A1 (fr) *	1984-03-19	1985-09-25	Ciba-Geigy Ag	Dérivés de la purine pour la régulation de croissance des plantes
GB8408615D0 (en) *	1984-04-04	1984-05-16	Wellcome Found	Heterocyclic compounds
US5310731A (en) *	1984-06-28	1994-05-10	Whitby Research, Inc.	N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US5175273A (en) *	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
GB2226027B (en) *	1988-12-13	1992-05-20	Sandoz Ltd	Adenosine derivatives,their production and use
US5063245A (en) *	1990-03-28	1991-11-05	Nova Pharmaceutical Corporation	Corticotropin-releasing factor antagonism compounds
US5240937A (en) *	1990-04-20	1993-08-31	Burroughs Wellcome Co.	Pharmaceutically active triazolopyridine compounds
CA2100863A1 (fr) *	1991-01-23	1992-07-24	David A. Bullough	Inhibiteurs de l'adenosine-kinase
US5250679A (en) *	1991-10-18	1993-10-05	Genentech, Inc.	Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
BR9206810A (pt) *	1991-11-25	1995-10-31	Pfizer	Derivados de indol
ES2130246T3 (es) *	1992-01-06	1999-07-01	Wellcome Found	Nucleosidos terapeuticos de la serie 2',3'-didesoxi-3'-fluoro-purina.
US5424297A (en) *	1992-04-27	1995-06-13	University Of Virginia Alumni Patents Foundation	Adenosine dextran conjugates
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
EP0764153A1 (fr) *	1994-06-06	1997-03-26	Pfizer Inc.	Pyrazoles substitues ayant une activite antagoniste du facteur liberant la corticotropine (flc)
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
ATE182332T1 (de) *	1994-06-16	1999-08-15	Pfizer	Pyrazolo und pyrrolopyridine
ATE182148T1 (de) *	1995-05-12	1999-07-15	Neurogen Corp	Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
ES2200039T3 (es) *	1995-12-08	2004-03-01	Pfizer Inc.	Derivados heterociclicos sustituidos como antagonistas de crf.

1997
- 1997-03-21 US US08/823,029 patent/US6107300A/en not_active Expired - Lifetime
- 1997-03-25 CN CN97194897A patent/CN1230184A/zh active Pending
- 1997-03-25 NZ NZ331874A patent/NZ331874A/xx unknown
- 1997-03-25 CZ CZ983040A patent/CZ304098A3/cs unknown
- 1997-03-25 JP JP53457797A patent/JP2002515032A/ja active Pending
- 1997-03-25 SI SI9720026A patent/SI9720026A/sl not_active IP Right Cessation
- 1997-03-25 EP EP97916991A patent/EP0935601A4/fr not_active Withdrawn
- 1997-03-25 KR KR1019980707661A patent/KR20000005037A/ko not_active Withdrawn
- 1997-03-25 AU AU25458/97A patent/AU2545897A/en not_active Abandoned
- 1997-03-25 BR BR9708261-9A patent/BR9708261A/pt not_active IP Right Cessation
- 1997-03-25 WO PCT/US1997/004852 patent/WO1997035539A2/fr not_active Ceased
- 1997-03-25 EE EE9800329A patent/EE9800329A/xx unknown
- 1997-03-25 IL IL12631697A patent/IL126316A0/xx unknown
- 1997-03-25 HU HU9902340A patent/HUP9902340A3/hu unknown
- 1997-03-25 CA CA002250241A patent/CA2250241A1/fr not_active Abandoned
- 1997-03-25 PL PL97335258A patent/PL335258A1/xx unknown
- 1997-03-25 EA EA199800868A patent/EA199800868A1/ru unknown
- 1997-03-25 SK SK1317-98A patent/SK131798A3/sk unknown
- 1997-03-26 HR HR60/039,124A patent/HRP970173A2/hr not_active Application Discontinuation
1998
- 1998-09-22 NO NO984418A patent/NO984418L/no unknown
- 1998-10-30 LV LVP-98-195A patent/LV12262B/en unknown
2000
- 2000-03-14 US US09/525,619 patent/US6448261B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2545897A (en)	1997-10-17
WO1997035539A3 (fr)	1999-05-14
NZ331874A (en)	2000-03-27
US6107300A (en)	2000-08-22
HUP9902340A2 (hu)	1999-11-29
WO1997035539A2 (fr)	1997-10-02
HUP9902340A3 (en)	2001-02-28
CN1230184A (zh)	1999-09-29
CA2250241A1 (fr)	1997-10-02
BR9708261A (pt)	2001-12-04
JP2002515032A (ja)	2002-05-21
EP0935601A4 (fr)	2002-08-07
PL335258A1 (en)	2000-04-10
EP0935601A2 (fr)	1999-08-18
SK131798A3 (en)	2000-05-16
LV12262A (lv)	1999-04-20
EA199800868A1 (ru)	1999-04-29
EE9800329A (et)	1999-06-15
CZ304098A3 (cs)	1999-02-17
NO984418D0 (no)	1998-09-22
US6448261B1 (en)	2002-09-10
HRP970173A2 (en)	1999-08-31
IL126316A0 (en)	1999-05-09
LV12262B (en)	1999-10-20
KR20000005037A (ko)	2000-01-25
SI9720026A (sl)	1999-04-30

Publication	Publication Date	Title
NO984418L (no)	1998-11-03	Arylaminokondenserte pyridiner og pyrimidiner
DK0901374T3 (da)	2004-04-05	Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
DE69328975D1 (de)	2000-08-10	Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
TW237455B (fr)	1995-01-01
ATE50763T1 (de)	1990-03-15	Tetralin-derivate, ihre herstellung und verwendung.
PL293389A1 (en)	1992-07-13	Method of obtaining novel heterocyclic compounds
ATE264846T1 (de)	2004-05-15	Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
BG104597A (en)	2001-02-28	Inhibition of raf kinase using substituted heterocyclic ureas
CA2118704A1 (fr)	1993-04-01	Heterocycles azotes tricycliques fusionnes utilises comme antagonistes des recepteurs a substance p
TR199902357T2 (xx)	2000-05-22	Yeni bile�imler.
PT691128E (pt)	2003-02-28	Metodos de administracao de antagonistas de crf
ATE178886T1 (de)	1999-04-15	1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
DE3578063D1 (de)	1990-07-12	1-substituierte tetralinderivate, ihre herstellung und verwendung.
AU551066B2 (en)	1986-04-17	Pyridyl substituted pyridylalkyleneamino pyrimidones
NZ326675A (en)	2000-01-28	Oxazoline arthropodicides
ATE102626T1 (de)	1994-03-15	Heterocyclische verbindungen, ihre darstellung und verwendung.
BG103271A (en)	2000-05-31	Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
NZ333229A (fr)	2000-01-28
TR199901395T2 (xx)	1999-11-22	Yeni karboksi ikameli siklik karboksamid t�revleri.
GR3002829T3 (en)	1993-01-25	4-nitrogen substituted isoquinolinol compounds having cardiotonic, phosphodiesterase fraction iii inhibiting properties and/or renal vasodilating properties
ES8604853A1 (es)	1986-03-01	Un metodo para la preparacion de un derivado de acetileno.
ATE41662T1 (de)	1989-04-15	Derivate von dihydro-1h-pyrrolo(1,2-c>imidazol3,5-dion zur aktivierung des wahrnehmungsvermoegens.
DE59202242D1 (de)	1995-06-22	Ethanoladdukte von 6-sulfonylsubstituierten 3-Hydroxychromanen und ihre Verwendung als Inhalationsmittel bei Krankheiten.
DE69210255D1 (de)	1996-05-30	THIENOPYRAZIN-2,3-DIONE VERWENDBAR BEI DER BEHANDLUNG VON ZNS-STöRUNGEN, UND IHRE HERSTELLUNG.
DE69015411D1 (de)	1995-02-09	5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one und -thione und deren Verwendung bei der Vorbeugung und und Behandlung von AIDS.